Amarna Therapeutics B.V.
- Biotech or pharma, therapeutic R&D
Amarna Therapeutics is a preclinical biotechnology company advancing Nimvec™, a proprietary, non-immunogenic viral platform based on the macaque polyomavirus SV40 that enables repeat dosing. As such, our Nimvec™ vectors can not only be employed for conventional gene replacement therapies but also as tolerogenic vectors. By promoting antigen-specific immune tolerance, NimvecTM vectors offer a novel precision medicine approach to address high unmet need autoimmune and inflammatory diseases.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}